Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

SEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that a poster presentation titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome" was presented at the AACR Special Conference in Cancer Research:

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Tue, 21 Jul 2026 08:30:00 -0400

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome

Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy

Tue, 07 Jul 2026 07:50:26 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Atossa Genetics (NASDAQ: ATOS) with a Buy rating and a price target of $12.00.

The analyst comments "We are initiating coverage of Atossa Therapeutics with a BUY rating and a $12 price target based on the company’s ownership of a uniquely versatile, next‑generation estrogen receptor modulator/degrader with validated clinical activity across breast cancer, and emerging preclinical and class‑based proof‑of‑concept in two high‑value rare disease indications that carry significant regulatory incentives."

For an analyst ratings summary and ratings history on Atossa Genetics click here. For more ratings news on Atossa Genetics

Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy

Tue, 07 Jul 2026 07:50:26 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Atossa Genetics (NASDAQ: ATOS) with a Buy rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Atossa Genetics click here. For more ratings news on Atossa Genetics

Atossa Therapeutics closes $4.5 million registered direct offering

Fri, 12 Jun 2026 17:31:21 -0400

Atossa Therapeutics, Inc. (NASDAQ: ATOS) completed a registered direct offering that raised $4.5 million in gross proceeds before deducting placement agent fees and other offering expenses, according to a company statement.

The Seattle-based clinical-stage biopharmaceutical company sold 1,363,637 shares of common stock at $0.18 per share, along with Series A and Series B warrants to purchase an additional 1,363,637 shares each. The warrants become exercisable six months after issuance, with Series A warrants expiring after 5.5 years and Series B warrants expiring after two years.

If all warrants are exercised for cash, the company could receive up to an additional $12 million

Atossa Therapeutics closes $4.5 million registered direct offering

Fri, 12 Jun 2026 17:31:21 -0400

If all warrants are exercised for cash, the company could receive up to an additional $12 million

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Fri, 12 Jun 2026 17:30:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Form 424B5 ATOSSA THERAPEUTICS,

Fri, 12 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26638816.html

Form 424B5 ATOSSA THERAPEUTICS,

Fri, 12 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26638816.html

Atossa Therapeutics raises $4.5 million in registered direct offering

Thu, 11 Jun 2026 08:01:45 -0400

Atossa Therapeutics Inc. (NASDAQ: ATOS) entered into a securities purchase agreement with institutional investors for a registered direct offering expected to generate $4.5 million in gross proceeds before fees and expenses.

The Seattle-based biopharmaceutical company will sell 1,363,638 shares of common stock at $0.18 per share, along with Series A and Series B warrants to purchase additional shares. The Series A warrants expire 5.5 years from issuance, while Series B warrants expire after two years. Both warrant series become exercisable six months following issuance.

If all warrants are exercised for cash, the company could receive an additional $12 million in gross proceeds,

Atossa Therapeutics raises $4.5 million in registered direct offering

Thu, 11 Jun 2026 08:01:45 -0400

If all warrants are exercised for cash, the company could receive an additional $12 million in gross proceeds,

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Thu, 11 Jun 2026 08:00:00 -0400

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

Form 8-K ATOSSA THERAPEUTICS, For: Jun 10

Thu, 11 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26632812.html

StreetInsider.com News Articles

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy

Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy

Atossa Therapeutics closes $4.5 million registered direct offering

Atossa Therapeutics closes $4.5 million registered direct offering

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Form 424B5 ATOSSA THERAPEUTICS,

Form 424B5 ATOSSA THERAPEUTICS,

Atossa Therapeutics raises $4.5 million in registered direct offering

Atossa Therapeutics raises $4.5 million in registered direct offering

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Form 8-K ATOSSA THERAPEUTICS, For: Jun 10